Skip to main content
Signal8

Optimi Health Corp. (OPTH)

Based in Princeton, Canada, Optimi Health Corp., established in 2020, is a Canadian entity focused on manufacturing pharmaceutical and nutraceutical products. The company produces and supplies controlled substances, including finalized MDMA and psilocybin drug products, directly to authorized clinics, pharmacies, research trials, and collaborative partners. Their diverse product portfolio extends to MDMA, natural psilocybin, psilocin, other psychedelic compounds, and functional mushrooms, all derived from botanical sources and aimed at the health and wellness market. Optimi Health's operations span cultivation, processing, and distribution of raw mushroom biomass, alongside the creation of mushroom extracts, pharmaceutical drug products, and dietary supplements. These items are available for purchase through the Amazon marketplace, via distributors and brokers, and directly online.

Sector: Pharmaceutical Preparations

Industry: Drug Manufacturers - Specialty & Generic

Optimi Health Corp. logo

Optimi Health Corp.

NASDAQ:OPTHHealthcare
AH-4.63%$2.38
Close$2.50+6.84%
Mkt Cap$14.31M
Float4.88M
O/S5.73M
VOL33K sh
$ Vol$77K
RVOL0.90×
Inst Own10.7%
SI0.5%
Dilution
Optimi Health Corp. logoNASDAQ:OPTHAH$2.38-4.63%
Pipeline1 lead-sponsored trial·0 active0 completed

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
  • Early Phase 1
    Withdrawn

    Mood and Cognitive Effects of Psilocybin in Healthy Participants

    Psilocybin, Inonotus Obliquus Whole Extract

    Mood Disturbance, Mood Change +8

    Enrollment
    0
    Start
    Jan 2023est.
    Primary Completion
    Aug 2023est.
    Completion
    Dec 2023est.
    NCT05252598
Search ClinicalTrials.gov for “Optimi Health”